Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 11, 2008

Newron Acquires Hunter-Fleming for $11.6M Upfront

  • Newron Pharmaceuticals, which is focused on CNS and pain therapies, will acquire Hunter-Fleming, a U.K. biopharmaceutical company developing new medicines to treat neurodegenerative and inflammatory disorders.

    The agreement provides for the acquisition of 100% of the issued share capital of Hunter-Fleming. Newron will make an upfront payment of 8 million ($11.6 million), minus net debt, for the 2/3 fully diluted share capital of Hunter-Fleming, in newly issued Newron shares. In addition, success-based milestones related to the Hunter-Fleming programs will be made up to a maximum of 17 million ($24.65 million).

    The acquisition of Hunter-Fleming enlarges Newron’s clinical-stage pipeline, particularly in the area of neuroinflammation. Hunter-Fleming has three compounds in various phases of clinical development and one in discovery.

    HF0220 is a broad-spectrum neuroprotective agent with an ongoing Phase II safety and tolerability study exploring biological markers in patients with Alzheimer’s disease, a Phase II study in rheumatoid arthritis will be initiated in late 2008. HF0420 is a low molecular weight oligosaccharide in Phase I for prevention of anticancer therapy-induced neuropathy. HF0299 is a naturally occurring human steroid in Phase I with potential for the treatment of neuropathic pain, and HF1220 is a second-generation neuroprotective compound series in the discovery phase.

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »